Skip to content

Study · Observational study · n = 594 · 2022

9 results

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).

Berra CC, Rossi MC, Mirani M, Ceccarelli Ceccarelli D, Romano C, Sassi L, Peretti E, Favacchio G, Pastore I, Folini L, Graziano G, Lunati ME, Solerte SB, Fiorina P

Frontiers in endocrinology18 Jan 2023Cited by 25 (Europe PMC)

PMID36743930 (opens in a new tab)PMCIDPMC9889982 (opens in a new tab)DOI10.3389/fendo.2022.1099451 (opens in a new tab)PepBankPUB-36743930
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

IntroductionAim of the present study was to evaluate the real-world impact of once-weekly (OW) subcutaneous semaglutide on different end-points indicative of metabolic control, cardiovascular risk factors, and beta-cell function in type 2 diabetes (T2D).MethodsThis was a retrospective, observational study conducted in 5 diabetes clinics in Italy. Changes in HbA1c, fasting blood glucose (FBG), body weight, blood pressure, lipid profile, renal function, and beta-cell function (HOMA-B) during 12 months were evaluated.ResultsOverall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years). After 6 months of treatment with OW semaglutide, HbA1c levels were reduced by 0.90%, FBG by 26 mg/dl, and body weight by 3.43 kg. Systolic blood pressure, total and LDL-cholesterol significantly improved. Benefits were sustained at 12 months. Renal safety was documented. HOMA-B increased from 40.2% to 57.8% after 6 months (p<0.0001).DiscussionThe study highlighted benefits of semaglutide on metabolic control, multiple CV risk factors, and renal safety in the real-world. Semaglutide seems to be an advisable option for preservation of β-cell function and early evidence suggests it might have a role in modifying insulin resistance (HOMA-IR), the pathogenetic basis of prediabetes and T2D.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, HbA1c fell by 0.90% after 6 months of once-weekly subcutaneous semaglutide.

    In plain wordsIn adults with type 2 diabetes, HbA1c fell after 6 months of weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change at 6 months
    Study

    n = 594

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    HbA1c reduction
    0.9%
    6 months

    Source sentences

    Summary
    After 6 months of treatment with OW semaglutide, HbA1c levels were reduced by 0.90%, FBG by 26 mg/dl, and body weight by 3.43 kg.
    2 context sentences
    Summary · context
    This was a retrospective, observational study conducted in 5 diabetes clinics in Italy.
    Summary · context
    Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years).
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, fasting blood glucose fell by 26 mg/dl after 6 months of once-weekly subcutaneous semaglutide.

    In plain wordsIn adults with type 2 diabetes, fasting blood glucose fell after 6 months of weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting blood glucose change at 6 months
    Study

    n = 594

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    FBG reduction
    26 mg/dl
    6 months

    Source sentences

    Summary
    After 6 months of treatment with OW semaglutide, HbA1c levels were reduced by 0.90%, FBG by 26 mg/dl, and body weight by 3.43 kg.
    2 context sentences
    Summary · context
    This was a retrospective, observational study conducted in 5 diabetes clinics in Italy.
    Summary · context
    Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years).
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, body weight fell by 3.43 kg after 6 months of once-weekly subcutaneous semaglutide.

    In plain wordsIn adults with type 2 diabetes, body weight fell after 6 months of weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at 6 months
    Study

    n = 594

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Body weight reduction
    3.43 kg
    6 months

    Source sentences

    Summary
    After 6 months of treatment with OW semaglutide, HbA1c levels were reduced by 0.90%, FBG by 26 mg/dl, and body weight by 3.43 kg.
    2 context sentences
    Summary · context
    This was a retrospective, observational study conducted in 5 diabetes clinics in Italy.
    Summary · context
    Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years).
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, systolic blood pressure improved significantly with once-weekly subcutaneous semaglutide.

    In plain wordsIn adults with type 2 diabetes, systolic blood pressure improved with weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 594

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Systolic blood pressure, total and LDL-cholesterol significantly improved
    2 context sentences
    Summary · context
    This was a retrospective, observational study conducted in 5 diabetes clinics in Italy.
    Summary · context
    Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years).
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, total cholesterol improved significantly with once-weekly subcutaneous semaglutide.

    In plain wordsIn adults with type 2 diabetes, total cholesterol improved with weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal cholesterol
    Study

    n = 594

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Systolic blood pressure, total and LDL-cholesterol significantly improved.
    2 context sentences
    Summary · context
    This was a retrospective, observational study conducted in 5 diabetes clinics in Italy.
    Summary · context
    Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years).
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, LDL-cholesterol improved significantly with once-weekly subcutaneous semaglutide.

    In plain wordsIn adults with type 2 diabetes, LDL-cholesterol improved with weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL-cholesterol
    Study

    n = 594

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Systolic blood pressure, total and LDL-cholesterol significantly improved.
    2 context sentences
    Summary · context
    This was a retrospective, observational study conducted in 5 diabetes clinics in Italy.
    Summary · context
    Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years).
  7. 07HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, HOMA-B increased from 40.2% to 57.8% after 6 months of once-weekly subcutaneous semaglutide.

    In plain wordsIn adults with type 2 diabetes, a measure of beta-cell function rose after 6 months of weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseBeta-cell function (HOMA-B) at 6 months
    Study

    n = 594

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    HOMA-B baseline
    40.2%
    baseline
    HOMA-B
    57.8%
    6 months

    Source sentences

    Summary
    HOMA-B increased from 40.2% to 57.8% after 6 months (p<0.0001).
    2 context sentences
    Summary · context
    This was a retrospective, observational study conducted in 5 diabetes clinics in Italy.
    Summary · context
    Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years).
  8. 08HumanObservational studySafety outcome

    In adults with type 2 diabetes, renal safety of once-weekly subcutaneous semaglutide was documented.

    In plain wordsIn adults with type 2 diabetes, weekly semaglutide showed no kidney safety problem in this study.

    Peptide
    Semaglutide
    Outcome
    No significant changeRenal safety
    Study

    n = 594

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Renal safety was documented.
    2 context sentences
    Summary · context
    This was a retrospective, observational study conducted in 5 diabetes clinics in Italy.
    Summary · context
    Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years).
  9. 09HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the benefits of once-weekly subcutaneous semaglutide were sustained at 12 months.

    In plain wordsIn adults with type 2 diabetes, the benefits of weekly semaglutide lasted to 12 months.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedPersistence of benefits at 12 months
    Study

    n = 594

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Benefits were sustained at 12 months.
    2 context sentences
    Summary · context
    This was a retrospective, observational study conducted in 5 diabetes clinics in Italy.
    Summary · context
    Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.